

CERTIFICATE

Survey of 10 May 2024

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Pancreas/Gastrointestinal Tract (300):

Validity 12 months:

C-Peptide
Insulin

(R) analysis is subject to the RiliBÄK

Customer:
10015026
Vseobecna fakulni nemocnice v Praze
ÚLBLD - Centralni laboratoř
RNDr. Hana Benáková
U Nemocnice 2
12808 Praha 2

Düsseldorf, 21 May 2024



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. rer. nat. Dr. med. Jürgen Durner
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 10 May 2024

You have participated in the External Quality Assessment with the following analysis

Pancreas/Gastrointestinal Tract (300):

C-Peptide
Gastrin
Insulin

(R) analysis is subject to the RiliBÄK

Customer:
10015026
Vseobecna fakulni nemocnice v Praze
ÚLBD - Centralni laboratoř
RNDr. Hana Benáková
U Nemocnice 2
12808 Praha 2

Düsseldorf, 21 May 2024



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. rer. nat. Dr. med. Jürgen Durner
(Adviser)



Listing and evaluation of the results

10015026: Vseobecná fakultní nemocnice v Praze
ÚLBD - Centrální laboratoř
RNDr. Hana Benáková

Survey of 10 May 2024

Adviser:

Prof. Dr. rer. nat. Dr. med. Jürgen Durner
Labor Becker MVZ GbR
Führichstr. 70
81671 München

Tel.: +49 89 450 917 349
Fax: +49 89 450 917 6349
Mail: j.durner@labor-becker.de

300

Pancreas/Gastrointestinal Tract

Analyte	Sample	Unit	Your value	Target value	TV-Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
C-Peptide	31	µg/l	2.17	2.33	SV	1.63	3.03	-7.1%	-1,66	+	
	32		1.96	2.09	SV	1.46	2.72	-6.4%	-1,57	+	
Gastrin	31	ng/l	5.25	27.1	SV	14.9	39.3	-80.6%	-7,21	-	
	32		>1050	1802	SV	991	2613		-2,12	+	
Insulin	31	mU/l	14.6	17.1	SV	12.0	22.2	-14.6%	-2,67	+	
	32		21.6	25.0	SV	17.5	32.5	-13.6%	-2,33	+	

Analyte	Sample	Your unit	Stated value	Conversion factor	Method	Manufacturer	Device	Standard
C-Peptide	31	nmol/l	0.717	3.02	189	RO	RO55	
	32		0.648	3.02				
Gastrin	31	pmol/l	2.50	2.10	228	SNI	ZY99	
	32		>500	2.10				
Insulin	31	mU/l	14.6	1.00	189	RO	RO55	
	32		21.6	1.00				

Additional information on the evaluation is available for download in the RV-Online system in the column "Report".

Individual summary of results

10015026: Všeobecná fakultní nemocnice v Praze
 ÚLBLD - Centrální laboratoř
 RNDr. Hana Benáková

Survey of 10 May 2024

300



Pancreas/Gastrointestinal Tract

C-Peptide (µg/l, N = 191)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
Abbott	31	1.97	1.38 - 2.56	1.97	4.72	20	100	100
	32	1.64	1.15 - 2.13	1.64	4.15	20	100	100
Siemens Atellica IM	31	1.84	1.29 - 2.39	1.84	5.54	16	100	100
	32	1.77	1.24 - 2.30	1.77	5.93	16	100	100
Siemens other	31	1.95	1.37 - 2.54	1.95	5.95	22	100	100
	32	1.68	1.18 - 2.18	1.68	4.23	22	100	100
Diasorin	31	2.12	1.48 - 2.76	2.12	5.05	31	100	100
	32	2.16	1.51 - 2.81	2.16	4.58	31	100	100
Roche	31	2.33	1.63 - 3.03	2.33	4.25	100	100	98.0
	32	2.09	1.46 - 2.72	2.09	4.07	100	98.0	
other providers (1)	31	1.75	1.22 - 2.28	1.75	22.9	2		
	32	1.44	1.01 - 1.87	1.44	28.4	2		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 99%





Gastrin (ng/l, N = 34)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
RIA (1)	31	48.2	26.5 - 69.9	48.2	33.6	4		
	32	898	235 - 1561	898	39.4	4		
other method	31	27.1	14.9 - 39.3	27.1	11.2	30	96.7	93.3
	32	1802	991 - 2613	1802	19.6	30	96.7	

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 94,1%



Insulin (mU/l, N = 157)										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
Abbott	31	11.6	8.12	-	15.1	11.6	6.06	22	95.5	95.5
	32	19.8	13.9	-	25.7	19.8	5.25	22	100	
Beckmann Coulter (1)	31	11.8	8.26	-	15.3	11.8	5.26	4		
	32	18.8	13.2	-	24.4	18.8	6.60	4		
BAYER HEALTH (Siemens)	31	15.0	10.5	-	19.5	15.0	5.15	23	100	100
	32	23.9	16.7	-	31.1	23.9	3.51	23	100	
DPC BIERMANN (Siemens)	31	13.2	9.24	-	17.2	13.2	12.6	11	100	100
	32	19.9	13.9	-	25.9	19.9	9.90	11	100	
Diasorin	31	14.8	10.4	-	19.2	14.8	6.16	19	100	100
	32	26.1	18.3	-	33.9	26.1	5.75	19	100	
Roche	31	17.1	12.0	-	22.2	17.1	5.49	78	97.4	94.9
	32	25.0	17.5	-	32.5	25.0	5.84	78	96.2	

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 96,8%

